Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417551 | 0.81 | TSHR (0.47) | MEN1KMT2ACYP3A4CYP2C19MAPT | |
| SCHEMBL4132973 | 0.69 | — | — | |
| SCHEMBL4126824 | 0.69 | AKR1C1 (0.34) | MEN1KMT2ATSHR | |
| SCHEMBL9196415 | 0.68 | ALDH1A1 (0.30) | CYP3A4 | |
| SCHEMBL4124776 | 0.68 | MMP1 (0.35) | MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL10380439 | 0.67 | LMNA (0.32) | — | |
| SCHEMBL187155 | 0.66 | — | — | |
| SCHEMBL4122126 | 0.66 | — | — | |
| SCHEMBL8175504 | 0.66 | TSHR (0.30) | KMT2ATSHR | |
| SCHEMBL8167660 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298783-B1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | UNIV YALE (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9126971-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120252751-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8193165-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2298783-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | Yale University (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100048500-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-25 | — | — | US | disclosed |
| US-7589078-B2 | Using a dideoxy and didehydro nucleoside | YALE UNIVERSITY (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1653976-A4 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | UNIV YALE (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1653976-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | YALE UNIVERSITY (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011709-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | YALE UNIVERSITY (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048500-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | TYMP, ITPA, SAMHD1 | MEN1 4618/4885KMT2A 1891/4885CYP3A4 1115/4885 |
| US-20120252751-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | TYMP, ITPA, SAMHD1 | MEN1 4618/4885KMT2A 1891/4885CYP3A4 1115/4885 |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | CCR1, CCR4, CCR3 | MEN1 3929/4885KMT2A 4190/4885CYP3A4 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.